Stem-cell therapy for neurologic diseases

Abstract

With the advent of research on stem cell therapy for various diseases, an important need was felt in the field of neurological diseases. While congenital lesion may not be amenable to stem cell therapy completely, there is a scope of partial improvement in the lesions and halt in further progression. Neuro degenerative lesions like Parkinson's disease, multiple sclerosis and amyotrophic lateral sclerosis have shown improvement with stem cell therapy. This article reviews the available literature and summarizes the current evidence in the various neurologic diseases amenable to stem cell therapy, the plausible mechanism of action, ethical concerns with insights into the future of stem cell therapy.

Keywords

Neurologic diseases - stem cells - treatment modalities

• REFERENCES

• 1 Gore A, Li Z, Fung HL, Young JE, Agarwal S, Antosiewicz-Bourget J. et al. Somatic coding mutations in human induced pluripotent stem cells. Nature 2011; 471: 63-7
• 2 Yoo J, Kim HS, Hwang DY. Stem cells as promising therapeutic options for neurological disorders. J Cell Biochem 2013; 114: 743-53
• 3 Kim SU, de Vellis J. Stem cell-based cell therapy in neurological diseases: A review. J Neurosci Res 2009; 87: 2183-200
• 4 Hou L, Hong T. Stem cells and neurodegenerative diseases. Sci China C Life Sci 2008; 51: 287-94
• 5 Holden C. Neuroscience. Versatile cells against intractable diseases. Science 2002; 297: 500-2
• 6 Lescaudron L, Naveilhan P, Neveu I. The use of stem cells in regenerative medicine for Parkinson's and Huntington's diseases. Curr Med Chem 2012; 19: 6018-35
• 7 Kim SU, Lee HJ, Kim YB. Neural stem cell-based treatment for neurodegenerative diseases. Neuropathology 2013; 33: 491-504
• 8 Baetge EE. Neural stem cells for CNS transplantation. Ann N Y Acad Sci 1993; 695: 285-91
• 9 Conti L, Reitano E, Cattaneo E. Neural stem cell systems: Diversities and properties after transplantation in animal models of diseases. Brain Pathol 2006; 16: 143-54
• 10 Yan J, Xu L, Welsh AM, Hatfield G, Hazel T, Johe K. et al. Extensive neuronal differentiation of human neural stem cell grafts in adult rat spinal cord. PLoS Med 2007; 4: e39
• 11 Wichterle H, Lieberam I, Porter JA, Jessell TM. Directed differentiation of embryonic stem cells into motor neurons. Cell 2002; 110: 385-97
• 12 Gaspard N, Vanderhaeghen P. Mechanisms of neural specification from embryonic stem cells. Curr Opin Neurobiol 2010; 20: 37-43
• 13 Satija NK, Singh VK, Verma YK, Gupta P, Sharma S, Afrin F. et al. Mesenchymal stem cell-based therapy: A new paradigm in regenerative medicine. J Cell Mol Med 2009; 13: 4385-402
• 14 Yamanaka S. Induction of pluripotent stem cells from mouse fibroblasts by four transcription factors. Cell Prolif 2008; 41 Suppl (Suppl. 01) 51-6
• 15 Yakubov E, Rechavi G, Rozenblatt S, Givol D. Reprogramming of human fibroblasts to pluripotent stem cells using mRNA of four transcription factors. Biochem Biophys Res Commun 2010; 394: 189-93
• 16 Sharma S, Gupta DK, Venugopal P, Kumar L, Dattagupta S, Arora MK. Therapeutic use of stem cells in congenital anomalies: A pilot study. J Indian Assoc Pediatr Surg 2006; 11: 211-7
• 17 Costa C, Comabella M, Montalban X. Stem cell-based treatment of neurologic diseases. Med Clin (Barc) 2012; 139: 208-14
• 18 Lindvall O, Kokaia Z, Martinez-Serrano A. Stem cell therapy for human neurodegenerative disorders-how to make it work. Nat Med 2004; 10: S42-50
• 19 Lunn JS, Sakowski SA, Feldman EL. Stem cell technology for neurodegenerative diseases. Ann Neurol 2011; 70: 353-61
• 20 Hess DC, Borlongan CV. Stem cells and neurological diseases. Cell Prolif 2008; 41 Suppl (Suppl. 01) 94-114
• 21 Suzuki M, Svendsen CN. Combining growth factor and stem cell therapy for amyotrophic lateral sclerosis. Trends Neurosci 2008; 31: 192-8
• 22 Lunn JS, Hefferan MP, Marsala M, Feldman EL. Stem cells: Comprehensive treatments for amyotrophic lateral sclerosis in conjunction with growth factor delivery. Growth Factors 2009; 27: 133-40
• 23 Behrstock S, Ebert AD, Klein S, Schmitt M, Moore JM, Svendsen CN. Lesion-induced increase in survival and migration of human neural progenitor cells releasing GDNF. Cell Transplant 2008; 17: 753-62
• 24 Ebert AD, Barber AE, Heins BM, Svendsen CN. Ex vivo delivery of GDNF maintains motor function and prevents neuronal loss in a transgenic mouse model of Huntington's disease. Exp Neurol 2010; 224: 155-62
• 25 Tuszynski MH, Thal L, Pay M, Salmon DP, UHS. Bakay R. et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 2005; 11: 551-5
• 26 Drapeau E, Nora Abrous D. Stem cell review series: Role of neurogenesis in age-related memory disorders. Aging Cell 2008; 7: 569-89
• 27 Li G, Peskind ER, Millard SP, Chi P, Sokal I, Yu CE. et al. Cerebrospinal fluid concentration of brain-derived neurotrophic factor and cognitive function in non-demented subjects. PLoS One 2009; 4: e5424
• 28 Tuszynski MH. Nerve growth factor gene therapy in Alzheimer disease. Alzheimer Dis Assoc Disord 2007; 21: 179-89
• 29 Shruster A, Melamed E, Offen D. Neurogenesis in the aged and neurodegenerative brain. Apoptosis 2010; 15: 1415-21
• 30 Morizane A, Darsalia V, Guloglu MO, Hjalt T, Carta M, Li JY. et al. A simple method for large-scale generation of dopamine neurons from human embryonic stem cells. J Neurosci Res 2010; 88: 3467-78
• 31 Cui YF, Hargus G, Xu JC, Schmid JS, Shen YQ, Glatzel M. et al. Embryonic stem cell-derived L1 overexpressing neural aggregates enhance recovery in Parkinsonian mice. Brain 2010; 133: 189-204
• 32 Cooper O, Hargus G, Deleidi M, Blak A, Osborn T, Marlow E. et al. Differentiation of human ES and Parkinson's disease iPS cells into ventral midbrain dopaminergic neurons requires a high activity form of SHH, FGF8a and specific regionalization by retinoic acid. Mol Cell Neurosci 2010; 45: 258-66
• 33 Xiong N, Zhang Z, Huang J, Chen C, Zhang Z, Jia M. et al. VEGF-expressing human umbilical cord mesenchymal stem cells, an improved therapy strategy for Parkinson's disease. Gene Ther 2011; 18: 394-402
• 34 Garbayo E, Montero-Menei CN, Ansorena E, Lanciego JL, Aymerich MS, Blanco-Prieto MJ. Effective GDNF brain delivery using microspheres--a promising strategy for Parkinson's disease. J Control Release 2009; 135: 119-26
• 35 Ebert AD, Beres AJ, Barber AE, Svendsen CN. Human neural progenitor cells over-expressing IGF-1 protect dopamine neurons and restore function in a rat model of Parkinson's disease. Exp Neurol 2008; 209: 213-23
• 36 Clelland CD, Barker RA, Watts C. Cell therapy in Huntington disease. Neurosurg Focus 2008; 24: E9
• 37 Kelly CM, Dunnett SB, Rosser AE. Medium spiny neurons for transplantation in Huntington's disease. Biochem Soc Trans 2009; 37: 323-8
• 38 Nakao N, Ogura M, Nakai K, Itakura T. Embryonic striatal grafts restore neuronal activity of the globus pallidus in a rodent model of Huntington's disease. Neuroscience 1999; 88: 469-77
• 39 Olson SD, Pollock K, Kambal A, Cary W, Mitchell GM, Tempkin J. et al. Genetically engineered mesenchymal stem cells as a proposed therapeutic for Huntington's disease. Mol Neurobiol 2012; 45: 87-98
• 40 McBride JL, Behrstock SP, Chen EY, Jakel RJ, Siegel I, Svendsen CN. et al. Human neural stem cell transplants improve motor function in a rat model of Huntington's disease. J Comp Neurol 2004; 475: 211-9
• 41 Maucksch C, Vazey EM, Gordon RJ, Connor B. Stem cell-based therapy for Huntington's disease. J Cell Biochem 2013; 114: 754-63
• 42 Rosser A, Svendsen CN. Stem cells for cell replacement therapy: A therapeutic strategy for HD?. Mov Disord 2014; 29: 1446-54
• 43 Nicoleau C, Viegas P, Peschanski M, Perrier AL. Human pluripotent stem cell therapy for Huntington's disease: Technical, immunological, and safety challenges human pluripotent stem cell therapy for Huntington's disease: Technical, immunological, and safety challenges. Neurotherapeutics 2011; 8: 562-76
• 44 Garbuzova-Davis S, Willing AE, Zigova T, Saporta S, Justen EB, Lane JC. et al. Intravenous administration of human umbilical cord blood cells in a mouse model of amyotrophic lateral sclerosis: Distribution, migration, and differentiation. J Hematother Stem Cell Res 2003; 12: 255-70
• 45 Suzuki M, McHugh J, Tork C, Shelley B, Hayes A, Bellantuono I. et al. Direct muscle delivery of GDNF with human mesenchymal stem cells improves motor neuron survival and function in a rat model of familial ALS. Mol Ther 2008; 16: 2002-10
• 46 Lunn JS, Sakowski SA, Federici T, Glass JD, Boulis NM, Feldman EL. Stem cell technology for the study and treatment of motor neuron diseases. Regen Med 2011; 6: 201-13
• 47 Corti S, Nizzardo M, Nardini M, Donadoni C, Salani S, Ronchi D. et al. Neural stem cell transplantation can ameliorate the phenotype of a mouse model of spinal muscular atrophy. J Clin Invest 2008; 118: 3316-30
• 48 Corti S, Nizzardo M, Nardini M, Donadoni C, Salani S, Ronchi D. et al. Embryonic stem cell-derived neural stem cells improve spinal muscular atrophy phenotype in mice. Brain 2010; 133: 465-81
• 49 Shinozuka K, Dailey T, Tajiri N, Ishikawa H, Kaneko Y, Borlongan CV. Stem cell transplantation for neuroprotection in stroke. Brain Sci 2013; 3: 239-61
• 50 Dailey T, Metcalf C, Mosley YI, Sullivan R, Shinozuka K, Tajiri N. et al. An update on translating stem cell therapy for stroke from bench to bedside. J Clin Med 2013; 2: 220-41
• 51 Tang Y, Yasuhara T, Hara K, Matsukawa N, Maki M, Yu G. et al. Transplantation of bone marrow-derived stem cells: A promising therapy for stroke. Cell Transplant 2007; 16: 159-69
• 52 Sinden JD, Vishnubhatla I, Muir KW. Prospects for stem cell-derived therapy in stroke. Prog Brain Res 2012; 201: 119-67
• 53 Mendez-Otero R, de Freitas GR, André C, de Mendonça ML, Friedrich M, Oliveira-Filho J. Potential roles of bone marrow stem cells in stroke therapy. Regen Med 2007; 2: 417-23
• 54 Bang OY. Current status of cell therapies in stroke. Int J Stem Cells 2009; 2: 35-44
• 55 Rosado-de-Castro PH, Pimentel-Coelho PM, da Fonseca LM, de Freitas GR, Mendez-Otero R. The rise of cell therapy trials for stroke: Review of published and registeredstudies. Stem Cells Dev 2013; 22: 2095-111
• 56 Nandoe Tewarie RS, Hurtado A, Bartels RH, Grotenhuis A, Oudega M. Stem cell–based therapies for spinal cord injury. J Spinal Cord Med 2009; 32: 105-14
• 57 Ronaghi M, Erceg S, Moreno-Manzano V, Stojkovic M. Challenges of stem cell therapy for spinal cord injury: Human embryonic stem cells, endogenous neural stem cells, or induced pluripotent stem cells?. Stem Cells 2010; 28: 93-9
• 58 Richardson RM, Singh A, Sun D, Fillmore HL, Dietrich 3^rd DW, Bullock MR. Stem cell biology in traumatic brain injury: Effects of injury and strategies for repair. Neurosurg 2010; 112: 1125-38
• 59 Kim HJ, Lee JH, Kim SH. Therapeutic effects of human mesenchymal stem cells on traumatic brain injury in rats: Secretion of neurotrophic factors and inhibition of apoptosis. J Neurotrauma 2010; 27: 131-8
• 60 Anbari F, Khalili MA, Bahrami AR, Khoradmehr A, Sadeghian F, Fesahat F. et al. Intravenous transplantation of bone marrow mesenchymal stem cells promotes neural regeneration after traumatic brain injury. Neural Regen Res 2014; 9: 919-23
• 61 Bakhtiary M, Marzban M, Mehdizadeh M, Joghataei MT, Khoei S, Pirhajati Mahabadi V. et al. Comparison of transplantation of bone marrow stromal cells (BMSC) and stem cell mobilization by granulocyte colony stimulating factor after traumatic brain injury in rat. Iran Biomed J 2010; 14: 142-9
• 62 Vawda R, Woodbury J, Covey M, Levison SW, Mehmet H. Stem cell therapies for perinatal brain injuries. Semin Fetal Neonatal Med 2007; 12: 259-72
• 63 Titomanlio L, Kavelaars A, Dalous J, Mani S, El Ghouzzi V, Heijnen C. et al. Stem cell therapy for neonatal brain injury: Perspectives and challenges. Ann Neurol 2011; 70: 698-712
• 64 Hargus G, Cui YF, Dihné M, Bernreuther C, Schachner M. In vitro generation of three-dimensional substrate-adherent embryonic stem cell-derived neural aggregates for application in animal models of neurological disorders. Curr Protoc Stem Cell Biol. 2012 Chapter 2:Unit 2D.11.
• 65 Alvarim LT, Nucci LP, Mamani JB, Marti LC, Aguiar MF, Silva HR. et al. Therapeutics with SPION-labeled stem cells for the main diseases related to brain aging: A systematic review. Int J Nanomedicine 2014; 9: 3749-70
• 66 Harrower TP, Barker RA. The emerging technologies of neural xenografting and stem cell transplantation for treating neurodegenerative disorders. Drugs Today (Barc) 2004; 40: 171-89
• 67 Lo B, Parham L. Resolving ethical issues in stem cell clinical trials: The example of Parkinson disease. J Law Med Ethics 2010; 38: 257-66
• 68 Barker RA, de Beaufort I. Scientific and ethical issues related to stem cell research and interventions inneurodegenerative disorders of the brain. Prog Neurobiol 2013; 110: 63-73
• 69 Ostenfeld T, Svendsen CN. Recent advances in stem cell neurobiology. Adv Tech Stand Neurosurg 2003; 28: 3-89
• 70 Dunnett SB, Rosser AE. Cell transplantation for Huntington's disease Should we continue?. Brain Res Bull 2007; 72: 132-47
• 71 Brundin P, Barker RA, Parmar M. Neural grafting in Parkinson's disease Problems and possibilities. Prog Brain Res 2010; 184: 265-94
• 72 Liu SP, Fu RH, Huang SJ, Huang YC, Chen SY, Chang CH. et al. Stem cell applications in regenerative medicine for neurological disorders. Cell Transplant 2013; 22: 631-7
• 73 Perrier A, Peschanski M. How can human pluripotent stem cells help decipher and cure Huntington's disease?. Cell Stem Cell 2012; 11: 153-61
• 74 Wijeyekoon R, Barker RA. Cell replacement therapy for Parkinson's disease. Biochim Biophys Acta 2009; 1792: 688-702
• 75 Luo Y, Fan Y, Chen X, Yu B, Yue L, Wang D. et al. Generation of induced pluripotent stem cells from Asian patients with chronic neurodegenerative diseases. J Reprod Dev 2012; 58: 515-21
• 76 Chen LW, Kuang F, Wei LC, Ding YX, Yung KK, Chan YS. Potential application of induced pluripotent stem cells in cell replacement therapy for Parkinson's disease. CNS Neurol Disord Drug Targets 2011; 10: 449-58
• 77 Feng Z, Gao F. Stem cell challenges in the treatment of neurodegenerative disease. CNS Neurosci Ther 2012; 18: 142-8
• 78 Balami JS, Fricker RA, Chen R. Stem cell therapy for ischaemic stroke: Translation from preclinical studies to clinical treatment. CNS Neurol Disord Drug Targets 2013; 12: 209-19
• 79 Mochizuki H, Choong CJ, Yasuda T. The promises of stem cells: Stem cell therapy for movement disorders. Parkinsonism Relat Disord 2014; 20 Suppl (Suppl. 01) S128-31
• 80 Meyer M, Jensen P, Rasmussen JZ. Stem cell therapy for neurodegenerative disorders. Ugeskr Laeger 2010; 172: 2604-7
• 81 Trueman RC, Klein A, Lindgren HS, Lelos MJ, Dunnett SB. Repair of the CNS using endogenous and transplanted neural stem cells. Curr Top Behav Neurosci 2013; 15: 357-98